You are here

Evan Lebois


Galloway CR, Ravipati K, Singh S, Lebois EP, et al. Hippocampal place cell dysfunction and the effects of muscarinic M1 receptor agonism in a rat model of Alzheimer’s disease. Hippocampus. 2018;28(8):568–585.

Lebois EP, Thorn C, Edgerton JR, et al. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer’s Disease. Neuropharmacology. 2018;136(C):362–373.

Lebois EP, Schroeder JP, Esparza TJ, et al. Disease-modifying effects of M1 muscarinic acetylcholine receptor activation in an Alzheimer’s disease mouse model. ACS Chem Neurosci.  2017;8(6):1177–1187.

Lebois EP, Trimper JB, Hu C, et al. Effects of selective M1 muscarinic receptor activation on hippocampal spatial representations and neuronal oscillations. ACS Chem Neurosci. 2016;7(10):1393–1405.

Lebois EP, Sheffler DJ, Digby GJ, et al. Development of a Highly Selective, Orally Bioavailable and CNS Penetrant M1 Agonist Derived from the MLPCN Probe, ML071. Bioorg Med Chem Lett. 2011;21(21):6451–6455.

Evan Lebois, Ph.D.

Evan Lebois is a senior research scientist in the Stanley Center for Psychiatric Research of the Broad Institute of MIT and Harvard, as a member of the translational research group under the direction of Jeff Cottrell. Lebois leads a drug discovery program for psychiatric disorders from initial screening through early clinical testing. This is done by leveraging the immense human genetics expertise of the Broad Institute community in order to enable us to develop novel, mechanism-based treatments. To accomplish this mission, Lebois leads both internal and external teams of investigators to develop therapeutics and conduct translational research into psychiatric disease mechanism across cellular, animal, and human levels of analysis. The team’s focus is on multiple aspects and stages of therapeutic development: novel target identification and validation through a deep understanding of how potential targets are linked to human disease; development and characterization of novel ligands; high-throughput screening and in vitro assay development; in vivo characterization; translational biomarker development; and human biology and clinical research in target patient populations.

Lebois came to the Broad Institute in August of 2018. Prior to that, he spent four years at Pfizer in the Neuroscience Research Unit, where he helped lead neuroscience drug discovery programs from early discovery through phase II, and where he also led the development of novel translational biomarker approaches to bridge preclinical drug development in animals and early clinical drug development in human patient populations. He has over 10 years of neurologic and psychiatric drug development expertise across numerous indications and stages of development.

Lebois holds a Ph.D. in neuroscience from Emory University, a M.S. degree in pharmacology from Vanderbilt University, and B.S. degrees in biology (molecular genetics concentration), biochemistry, and chemistry from the University of Delaware. Contact Evan Lebois via email at

April 2019